GLPwatch
Papers (12034)
Page 180 of 201, ranked by citation count.
- Efsubaglutide Alfa attenuates metabolic dysfunction-associated steatohepatitis in mice with improvements in second harmonic generation-derived fibrosis features.
- Risk of Dementia after initiation of GLP-1 RA versus long-acting insulin in patients with type 2 Diabetes mellitus.
- Tirzepatide for weight reduction in people without diabetes.
- A Systematic Review and Meta-Analysis of Semaglutide Effects on Adipose Tissue and Emerging Effects on Brain and Cognition.
- Structural and mechanistic insights into dual activation of cagrilintide in amylin and calcitonin receptors.
- Hypoglycaemic coma induced by a falsified semaglutide product: a case report.
- Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
- [Combination therapy with glucagon-like peptide-1 analogs and insulin: indications and contraindications in coronary artery disease patients].
- Impact of Tirzepatide Therapy on Thyroid Disease: Understanding Risks and Emerging Insights.
- Survodutide: a novel peptide for treatment of obesity and metabolic diseases.
- Impact of semaglutide pretreatment on reproductive outcomes in women with overweight and obesity with infertility: a real-world multicenter cohort study.
- Trends in utilization of glucagon-like peptide‑1 receptor agonists, sodium-glucose cotransporter‑2 inhibitors, and metabolic bariatric surgery in U.S. Adults with diabetes and obesity.
- Megestrol acetate as an overlooked cause of hyperglycemia in end-stage renal disease: A case of polypharmacy
- From pathobiology to prescribing in obesity-driven HFpEF: A systematic review and practical therapeutic framework.
- Retraction notice to "Dulaglutide mitigates high dietary fructose-induced renal fibrosis in rats through suppressing epithelial-mesenchymal transition mediated by GSK-3β/TGF-β1/Smad3 signaling pathways" [Life Sci. 309 (2022) 120999].
- [New hypoglycemic agents in type 2 diabetes].
- Is Weight Loss the Main Driver for A1C Improvement by Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists? A 2.5-Year Analysis in Real-World Clinical Practice.
- Surgery on Patients Taking Glucagon-Like Peptide-1 Receptor Agonists.
- Size-exclusion LC-UV/HRMS based method for the analysis of aggregates in synthetic GLP-1 analog liraglutide and evaluation of excipient impact on aggregation.
- The GLP-1-Mitochondria Axis in Metabolic Aging.
- Recommendation for Clarifying FDA Policy in Evaluating "Sameness" of Higher Order Structure for Generic Peptide Therapeutics.
- Efficacy and Safety of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Ventricular Arrhythmias and Cardiovascular Events: A Disease-Stratified Network Meta-Analysis.
- Clinical outcomes of glucagon-like peptide-1 receptor agonist therapy in kidney transplant recipients: a systematic review and meta-analysis.
- Semaglutide 2.4 mg Cardiometabolic Long-Term Effects in Patients With Obesity or Overweight in a Real-World Setting: A Retrospective Cohort Study in the United States (SMILE).
- Glucagon-like peptide 1 agonists for type 2 diabetes, weight loss, or both?
- Retatrutide and the urinary tract infection signal: Is the answer hidden in timing?
- Beyond GLP-1 Agonists: Plant-Derived Bioactive Compounds as Adjunctive Strategies for Obesity Management.
- GLP-1 Receptor Agonist Therapy for Obesity Under Japan's Optimal Use Guideline: A Prospective Real-World Study of Lifestyle Pre-Treatment, Time-Limited Treatment Cap, and Post-Cessation Regain.
- Retatrutide effects on diabetic rats' cognition.
- Injectable Schiff base-engineered hydrogel for spatiotemporal liraglutide delivery orchestrates diabetic periodontitis regression via multimodal microenvironment reprogramming.
- A Comprehensive Review on the Cardioprotective and Nephroprotective Effects of Semaglutide, and Its Therapeutic Efficacy and Mechanisms in Cardiorenal Syndrome.
- Topic and Sentiment Trends in Semaglutide Discussions on X: Subpopulation-Based Longitudinal Analysis.
- Preoperative liraglutide modulates control of fat and glucose metabolism during cardiopulmonary bypass surgery.
- Glycaemic changes during early semaglutide treatment: a case of pancreatic adenocarcinoma.
- Association between GLP-1 receptor agonists and alcohol-related hospitalisations among adults with alcohol use disorder: multi-target trial emulation study.
- Tirzepatide and Cardiometabolic Effects in Obese Non-diabetic Adults: A Systematic Review, Meta-Analysis, and Narrative Synthesis of Cardiovascular Outcomes.
- To Reenvision and Redefine: Considering the Role of Lifestyle Interventions in the New Era of Second-Generation Obesity Management Medications.
- Treating Prediabetes With Tirzepatide Helps Obese Patients Lose Weight and Decreases Likelihood of Type 2 Diabetes.
- Cost-effectiveness of incretin therapies: a Canadian lens on diabetes, obesity, and emerging indications.
- Glucagon-like peptide-1 receptor agonists in individuals with severe mental illness: A systematic review and meta-analysis of randomized controlled trials.
- Semaglutide and Non-arteritic Anterior Ischemic Optic Neuropathy: A Systematic Review and Narrative Synthesis.
- Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes.
- Effects of semaglutide on one-year medical costs among patients with obesity or overweight in US real world setting.
- Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial.
- A Cost-Effectiveness Model of Semaglutide 2.4 mg, Resmetirom 80 mg, and Resmetirom 100 mg Versus Standard of Care for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis in the United States.
- Liraglutide Nano-Preparation on Perioperative Neurocognitive Dysfunction in Aged Mice.
- Semaglutide alleviates osteoarthritis independent of weight loss via GLP-1R-mediated activation of autophagy through AKT/mTOR inhibition.
- [An historical overview of GLP-1/GIP incretins. From hormone to "swiss-army knife" medications].
- Health Care Costs and Use of Patients Prescribed Four Different Obesity Medications.
- Two-Year Biomarker Trends and Kidney/Mortality Outcomes After Semaglutide Versus Phentermine-Topiramate and Naltrexone-Bupropion in People With Obesity and Without Diabetes.
- Tirzepatide alters oncogenic signaling pathways in colorectal cancer cells in vitro.
- Effect of oral semaglutide on cardiometabolic risk factors in overweight and obese individuals with or without diabetes: a systematic review and meta-analysis.
- Glycemic and Economic Outcomes in Elderly Patients with Type 2 Diabetes Initiating Dulaglutide Versus Basal Insulin in a Real-World Setting in the United States: The DISPEL-Advance Study.
- Atypical retrobulbar optic neuropathy after semaglutide escalation.
- Disproportionality Analysis of Tirzepatide-Associated Ketoacidosis.
- Effect of Semaglutide on Measured vs Estimated Glomerular Filtration Rate.
- JPEN Journal Club 88. Determining the hypothesis of a study.
- Liraglutide therapy in an adolescent with Prader‑Willi syndrome and concomitant diabetes mellitus.
- Real-world use of oral semaglutide in adults with type 2 diabetes.
- Improved Physical, Emotional, and Social Well-Being in People Living With Obesity Treated With Semaglutide: A Plain Language Summary.